migalastat hydrochloride

DRUG3 trials

Sponsors

Amicus Therapeutics

Conditions

Fabry Disease

Phase 3

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

CompletedNCT00925301

Amicus TherapeuticsFabry Disease

Start: 2009-10-23End: 2014-01-29Updated: 2018-10-30

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

CompletedNCT01218659

Amicus TherapeuticsFabry Disease

Start: 2011-09-08End: 2015-05-28Updated: 2018-11-01

Open-Label Phase 3 Long-Term Safety Study of Migalastat

TerminatedNCT01458119

Amicus TherapeuticsFabry Disease

Start: 2011-10-14End: 2016-02-17Updated: 2018-10-02

Related Papers

Long-term efficacy of migalastat in females with Fabry disease.

2025-11-211 citations

Assessment of plasma lyso-Gb<sub>3</sub> for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.

2020-09-3038 citations

Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study

Molecular Genetics and Metabolism2020-08-1574 citations

Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.

2019-12-3011 citations

Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report

Case Reports in Obstetrics and Gynecology2019-12-223 citations

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial

UNC Libraries2019-08-18

Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study.

2019-02-0671 citations

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.

2018-04-2725 citations

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Journal of Medical Genetics2016-11-10370 citations

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

New England Journal of Medicine2016-08-10536 citations

Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A/AT1001) in healthy male Japanese subjects.

2013-07-246 citations